Lantern Pharma's LP-184 Cleared by EMA for Bladder Cancer Trial in Europe

Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study will be conducted at Rigshospitalet in Copenhagen, Denmark, and will enroll up to 39 patients. Participants will be prospectively selected based on PTGR1 overexpression and DNA-damage-repair deficiency, reflecting Lantern's precision oncology approach.

The trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies. This clearance marks a significant step for Lantern's pipeline, as LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, the company's wholly owned CNS-focused subsidiary. The study will further advance Lantern's AI-driven precision oncology strategy through its proprietary RADR platform, which leverages machine learning to identify patient populations most likely to respond.

Lantern Pharma is a clinical-stage precision oncology company that uses AI and its RADR platform to transform cancer therapy development. Its clinical pipeline includes LP-284, a TC-NER targeting compound in hematologic and solid tumors, and LP-300, a cisplatin/ethacraplatin analog being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, Lantern's withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform for the global biomedical community, representing a new revenue stream.

The EMA clearance underscores the potential of LP-184 in a difficult-to-treat cancer type and highlights the role of biomarker-driven trials in oncology. For more details, the full press release is available at https://ibn.fm/6ku4F. Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. Latest news and updates are available at https://ibn.fm/LTRN.